Fidelity Management & Research Company

Activity in this selectionOct 4, 2026 · Biotech · Jul 7, 2026

By stage

Series C+3

Biotech3

United States2

Australia1

3 in this selection

Aug 10

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

$90MSeries C

Role not disclosed

Jul 15

Develops lead-212 targeted alpha therapies to treat cancer

$315MSeries D

Role not disclosed

Jul 8

Develops allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies

$35MSeries C

Role not disclosed